CCPortal
DOI10.1093/toxsci/kfu200
Adverse Outcome Pathway Development II: Best Practices
Villeneuve, Daniel L.1; Crump, Doug2; Garcia-Reyero, Natalia3; Hecker, Markus4,5; Hutchinson, Thomas H.6; LaLone, Carlie A.1,7; Landesmann, Brigitte8; Lettieri, Teresa8; Munn, Sharon8; Nepelska, Malgorzata8; Ottinger, Mary Ann9; Vergauwen, Lucia10; Whelan, Maurice8
发表日期2014-12-01
ISSN1096-6080
卷号142期号:2页码:321-330
英文摘要

Organization of existing and emerging toxicological knowledge into adverse outcome pathway (AOP) descriptions can facilitate greater application of mechanistic data, including those derived through high-throughput in vitro, high content omics and imaging, and biomarker approaches, in risk-based decision making. The previously ad hoc process of AOP development is being formalized through development of internationally harmonized guidance and principles. The goal of this article was to outline the information content desired for formal AOP description and some rules of thumb and best practices intended to facilitate reuse and connectivity of elements of an AOP description in a knowledgebase and network context. For example, key events (KEs) are measurements of change in biological state that are indicative of progression of a perturbation toward a specified adverse outcome. Best practices for KE description suggest that each KE should be defined as an independent measurement made at a particular level of biological organization. The concept of "functional equivalence" can help guide both decisions about how many KEs to include in an AOP and the specificity with which they are defined. Likewise, in describing both KEs and evidence that supports a causal linkage or statistical association between them (ie, a key event relationship; KER), best practice is to build from and contribute to existing KE or KER descriptions in the AOP knowledgebase rather than creating redundant descriptions. The best practices proposed address many of the challenges and uncertainties related to AOP development and help promote a consistent and reliable, yet flexible approach.


英文关键词adverse outcome pathway;regulatory toxicology;predictive toxicology;extrapolation;knowledgebase
语种英语
WOS记录号WOS:000347617800002
来源期刊TOXICOLOGICAL SCIENCES
来源机构美国环保署
文献类型期刊论文
条目标识符http://gcip.llas.ac.cn/handle/2XKMVOVA/61788
作者单位1.US EPA, Mid Continent Ecol Div, Duluth, MN 55804 USA;
2.Environm Canada, Ecotoxicol & Wildlife Hlth Div, Ottawa, ON K1A 0H3, Canada;
3.Mississippi State Univ, Inst Genom Biocomp & Biotechnol, Starkville, MS 39762 USA;
4.Univ Saskatchewan, Sch Environm & Sustainabil, Saskatoon, SK S7N 5B3, Canada;
5.Univ Saskatchewan, Toxicol Ctr, Saskatoon, SK S7N 5B3, Canada;
6.Univ Plymouth, Sch Biol Sci, Plymouth PL4 8AA, Devon, England;
7.Univ Minnesota, Water Resources Ctr, St Paul, MN 55108 USA;
8.Commiss European Communities, Joint Res Ctr, I-21027 Ispra, Italy;
9.Univ Houston, Dept Biol & Biochem, Houston, TX 77004 USA;
10.Univ Antwerp, Dept Vet Sci, Zebrafishlab, B-2610 Antwerp, Belgium
推荐引用方式
GB/T 7714
Villeneuve, Daniel L.,Crump, Doug,Garcia-Reyero, Natalia,et al. Adverse Outcome Pathway Development II: Best Practices[J]. 美国环保署,2014,142(2):321-330.
APA Villeneuve, Daniel L..,Crump, Doug.,Garcia-Reyero, Natalia.,Hecker, Markus.,Hutchinson, Thomas H..,...&Whelan, Maurice.(2014).Adverse Outcome Pathway Development II: Best Practices.TOXICOLOGICAL SCIENCES,142(2),321-330.
MLA Villeneuve, Daniel L.,et al."Adverse Outcome Pathway Development II: Best Practices".TOXICOLOGICAL SCIENCES 142.2(2014):321-330.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Villeneuve, Daniel L.]的文章
[Crump, Doug]的文章
[Garcia-Reyero, Natalia]的文章
百度学术
百度学术中相似的文章
[Villeneuve, Daniel L.]的文章
[Crump, Doug]的文章
[Garcia-Reyero, Natalia]的文章
必应学术
必应学术中相似的文章
[Villeneuve, Daniel L.]的文章
[Crump, Doug]的文章
[Garcia-Reyero, Natalia]的文章
相关权益政策
暂无数据
收藏/分享

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。